Emily Bodnar’s score relies about the anticipation of major milestones for Agenus in the approaching year, specially the potential submitting of the Biologics License Software (BLA) for their lead drug candidate, botensilimab (bot). Agenus has dosed more than 900 individuals with bot across several stable tumors, demonstrating a motivation to in